Anita M Hennige (Sam Rose)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond Manuel, Anita M Hennige
Correction to: Dose-response effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024)
Rie Yazawa, Masahiro Ishida, Yesilda Balavarca, Anita M Hennige
A randomised Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes, obesity & metabolism (2023)
Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond Manuel, Anita M Hennige
Dose-response effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2023)
Susanna Bianzano, Anita M Hennige, Matias Nordaby, Leona Plum-Mörschel, Barbara Peil, Tim Heise
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. Diabetes, obesity & metabolism (2022)